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Résumé en
anglais
Cerebral Scedosporium infections usually occur in lung transplant recipients as well
as in immunocompetent patients in the context of near-drowning. Voriconazole is the
first-line treatment. The diffusion of voriconazole through the blood-brain barriers in
the context of cerebral infection and cyclosporine administration is crucial and
remains a matter of debate. To address this issue, the pharmacokinetics of
voriconazole were assessed in the plasma, cerebrospinal fluid (CSF), and brain, in an
experimental model of cerebral scedosporiosis in rats receiving or not cyclosporine. A
single dose of voriconazole (30 mg/kg, i.v.) was administrated to six groups of rats
randomized according to the infection status and the cyclosporine dosing regimen (no
cyclosporine, a single dose or three doses 15 mg/kg each). Voriconazole
concentrations in plasma, CSF, and brain samples were quantified using UPLC-MS/MS
and HPLC-UV methods and documented up to 48 hours after administration.
Pharmacokinetic parameters were estimated using a non-compartmental approach.
Voriconazole pharmacokinetic profiles were similar for plasma, CSF, and the brain in
all groups studied. Voriconazole Cmax and AUC0=>48h were significantly higher in
the plasma than in the CSF (CSF/plasma ratio, median [range] = 0.5 [0.39-0.55] for
AUC0=>48h and 0.47 [0.35 and 0.75] for Cmax). Cyclosporine administration was
significantly associated with an increase in voriconazole exposure in the plasma, CSF,
and brain. In the plasma but not in the brain, an interaction between the infection and
cyclosporine administration reduced the positive impact of cyclosporine on
voriconazole exposure. Together these results emphasize the impact of cyclosporine
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